Patient support programs for specialty therapies can have the right capabilities in place and still underperform.
The problem is often not a lack of support, technology, or expertise. It’s how those elements work together across the patient journey.
When enrollment, onboarding, monitoring, adherence support, and ongoing care operate as disconnected workstreams, gaps emerge between them. Patients can experience delays in starting therapy, missed opportunities for support, and fragmented experiences at the moments when continuity matters most.
RxPx helps pharmaceutical teams design, connect, and operate the therapy infrastructure needed to identify these gaps and address them before they affect patients.
This article outlines five areas pharmaceutical teams should assess when a patient support program is underperforming and where underlying infrastructure may be contributing to the problem.
Where Specialty Therapy Support Programs Fall Short
1. The Program Is Designed Around the Therapy, Not the Patient Journey
Many patient support programs are structured around the therapy’s clinical requirements: dosing schedules, administration requirements, monitoring protocols, and treatment milestones.
That clinical logic matters. But it doesn’t always reflect how patients actually experience treatment.
The importance of incorporating the patient perspective is increasingly recognized across the industry. The FDA’s Patient-Focused Drug Development guidance emphasizes systematically incorporating patients’ experiences, perspectives, needs, and priorities into drug development and evaluation.
The European Medicines Agency has similarly advanced work around patient experience data, including patient-reported outcomes, patient preferences, patient-generated digital data, and real-world data.
For patient support programs, that means looking beyond what the therapy requires clinically to understand what patients experience in the real world.
Access barriers, treatment delays, health literacy gaps, logistical challenges, and emotional isolation can all influence whether someone successfully starts and stays on therapy. These challenges can also change over time. What a patient needs before their first dose may be very different from what they need 30, 90, or 180 days into treatment.
Programs designed primarily around clinical requirements risk overlooking the real-world barriers that influence initiation, adherence, and long-term persistence.
Effective support starts with understanding the entire patient journey, then designing the infrastructure around the moments where patients are most likely to need additional support.
2. Handoffs Create Gaps Between Enrollment and Ongoing Support
Specialty therapy programs rarely depend on one team or system.
Patients may interact with HCPs, enrollment teams, pharmacies, laboratories, nurses, navigators, digital platforms, and other support services throughout their treatment journey.
The individual capabilities may work well. The risk emerges in the handoffs between them.
A patient may complete enrollment but wait days for the next step. A consent may not trigger the appropriate workflow. A lab result may sit outside the patient support process. A patient showing signs of disengagement may need human intervention, but the right support team may not have visibility into what happened earlier in the journey.
This is an infrastructure gap, not simply a patient engagement problem.
When enrollment, onboarding, education, monitoring, and ongoing support operate as disconnected workstreams, the patient journey becomes a series of handoffs rather than one coordinated experience.
Pharmaceutical teams should assess not only whether each capability exists, but whether information and accountability move with the patient from one stage to the next.
3. Patient Risk Is Identified Too Late
Retrospective reporting can tell you what happened.
It is less effective at telling you what needs attention now.
A missed lab requirement, change in symptoms, missed dose, decline in engagement, or lapsed refill can signal emerging patient risk. But those signals are only valuable if the program can identify them early and surface them to the appropriate person or workflow.
When teams depend primarily on retrospective reporting, they may discover patterns only after patients have already disengaged, experienced delays, or required additional intervention.
Connected programs create greater visibility across the patient journey. Patient-reported information, adherence behavior, monitoring requirements, support interactions, and other program signals can help teams understand where patients may be struggling and determine when additional support is needed.
This growing emphasis on meaningful patient-generated information is also reflected in regulatory thinking. FDA’s Patient-Focused Drug Development framework supports the systematic collection and use of patient experience data, while its guidance on identifying what matters to patients specifically addresses methods for understanding symptoms, treatment burden, and other issues important to patients.
For specialty therapies with significant safety, adherence, or monitoring requirements, earlier visibility gives teams more opportunity to act before a gap becomes a larger problem.
4. Technology Exists Without an Infrastructure Strategy
Adding another patient app, dashboard, or digital engagement tool to a fragmented support model does not make that model connected.
Technology can help deliver education, capture patient-reported information, support medication routines, monitor engagement, and identify emerging signals. But technology alone cannot solve disconnected workflows.
The goal isn’t more technology. It’s connected infrastructure around the therapy.
Patient, HCP, lab, pharmacy, and support-team workflows should operate as part of a coordinated system where each interaction can inform what happens next.
When a patient misses a required action, the program should know what needs to happen. When monitoring identifies a potential concern, the appropriate workflow should respond. When digital support is no longer enough, there should be a clear pathway to human intervention.
Technology becomes more valuable when it enables that coordination rather than becoming another standalone layer for patients, HCPs, or brand teams to manage.
5. Program Performance Is Measured by Outputs, Not Outcomes
Enrollment counts, call volumes, content views, app logins, and message opens can all provide useful information about program activity.
But activity alone does not demonstrate that a patient support program is working.
Outcome-focused measurement asks different questions:
- Are patients initiating therapy on time?
- Are they remaining engaged beyond enrollment?
- Where are patients dropping off?
- Are adherence and persistence holding at 90 days, 180 days, and beyond?
- Are emerging safety or adherence risks being identified early enough to support appropriate intervention?
- Which support activities are actually changing patient behavior or improving program performance?
The difference matters because high activity can coexist with poor outcomes.
Connected infrastructure gives pharmaceutical teams greater visibility into how engagement, adherence, monitoring, HCP workflows, and support interventions influence one another. That creates an opportunity not only to report on what happened, but to understand what is working, where patients are struggling, and where the program should adapt.
How to Assess Your Therapy Support Infrastructure
Every specialty therapy has points of vulnerability. The important question is whether your team can identify them while there is still time to act.
When a patient support program underperforms, adding another capability should not automatically be the first response. Start by identifying where the existing model is breaking down.
For pharmaceutical teams evaluating a current program or designing the next one, consider these questions:
- Does the support model reflect the real patient journey, including the barriers that influence initiation, adherence, and persistence?
- Are enrollment, onboarding, monitoring, and ongoing support connected, or dependent on manual handoffs?
- Can emerging patient risk be identified early enough for the appropriate team to act?
- Does technology connect the therapy ecosystem, or does it add another standalone workflow?
- Can patient, HCP, lab, pharmacy, and support-team interactions inform what happens next?
- Is there clear accountability when a patient moves between different parts of the support ecosystem?
- Are you measuring meaningful patient and program outcomes, or primarily activity metrics?
- Can insights from the program be used to continuously improve how patients are supported?
The answers can help distinguish between a missing capability and a deeper coordination problem.
From Patient Support to Connected Therapy Infrastructure
High-performing patient support programs are not defined by how many capabilities they have.
They are defined by how well those capabilities work together.
RxPx helps pharmaceutical teams identify where therapy infrastructure is exposed, then brings together the strategy, technology, human support, and operational workflows needed to close those gaps.
From patient and HCP engagement to monitoring, nurse-led support, AI-supported risk intelligence, and ongoing program insights, the goal is not to add another disconnected capability. It is to create a coordinated system around the therapy that helps teams see risk earlier, connect the right actions, and continuously improve program performance.
For teams preparing to launch a specialty therapy, starting early creates more opportunity to design these connections before patients enter the program. For established programs, assessing the infrastructure behind current performance can reveal where fragmentation is limiting results.
If your patient support program is underperforming, the first step isn’t necessarily adding more. It’s identifying where the current model is breaking down.
Book a Therapy Risk Assessment to identify where your therapy may be exposed and where stronger coordination could improve real-world performance.